Tissue and tumor distribution of 14C-penclomedine in rats

Clinical Cancer Research

Volumn 2, Issue 3, 1996, Pages 541-548

  O'Reilly, Seamus ^a   Hartman, Neil R ^b   Grossman, Stuart A ^a   Strong, John M ^b   Struck, Robert F ^c   Eller, Susan ^a   Lesser, Glenn J ^a   Donehower, Ross C ^a   Rowinsky, Eric K ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; DRUG METABOLITE; PENCLOMEDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG DISTRIBUTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; AUTORADIOGRAPHY; BRAIN; CARBON RADIOISOTOPES; KIDNEY; LIVER; MALE; NEOPLASMS, EXPERIMENTAL; PICOLINES; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 0029914440     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Plowman, J., Harrison, S. D. Jr , Dykes, D. J., Paull, K. D., Narayanan, V., Tobol, H. K., and Griswold, D. P., Jr. Preclinical antitumor activity of an α-picoline derivative, penclomedine (NSC 338720), on human and murine tumors. Cancer Res., 49: 1909-1915, 1989.
2. Harrison, S. D., Jr., Plowman, J., Dykes, D. J., Wand, W. R., and Griswold, D. P., Jr. Preclinical antitumor activity of penclomedine in mice: cross-resistance, schedule dependence, and oral activity against tumor xenografts in brain. Cancer Res., 51: 1979-1983, 1991.
3. Reid, J. M., Mathieson, D. A., Benson, L. M., Kuffel, M. J., and Ames, M M. Murine pharmacokinetics and metabolism of penclomedine [3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine. NSC 338720]. Cancer Res., 52: 2830-2834, 1992.
4. Hartman, N. R., Strong, J. M., and Collins, J. M. Metabolism of penclomedine by human liver preparations. Proc. Am. Assoc. Cancer Res., 35: 402, 1994.
5. Penclomedine. Investigators Brochure. Bethesda, MD: National Cancer Institute, 1992.
6. Berlin, J., Stewart, J., Tutsch, K., Storer, B., Arzoomanian, R., Alberti, D., Feierahend, C., and Wilding, G. Phase I and pharmacokinetic trial of penclomedine (NSC 338720) Proc. Am. Assoc. Cancer Res., 36 238, 1995
7. O'Reilly, S., Grochow, L., Donehower, R. C., Bowling, K., Chen, T. L., Sartorius, S., Roskes, E., Ludeman, S., Hartman, N., Strong, J , Struck, R., and Rowinsky, E. K. Phase I and pharmacologic studies of penclomedine, a novel alkylating agent with prominent preclinical activity in breast cancer Proc. Am. Soc. Clin. Oncol. Annu. Meet , 14: 471, 1995.
8. Rosso, R., Donelli, M. G., Franchi, G., and Garattini, S. Impairment of drug metabolism in tumor bearing animals. Eur. J. Cancer & Clin. Oncol , 7: 565-577, 1971.
9. Bartosek, I., Donelli, M. G., and Guaitani, A. Modification of drug metabolism induced in the host by the presence of a tumor. Recent Results Cancer Res., 49: 95-100, 1974.
10. Donelli, M. G., D'Incali, M., and Garattini, S. Pharmacokinetic studies of anticancer drugs in tumor bearing animals. Cancer Treat Rep., 68: 381-400, 1984.
11. Fetell, M. R., Grossman, S. A., Balmaceda, C., Leu, J. G., Erlanger, B. F., Rowinsky, E. K., Khandji, G., Yeu, N., and Zeltman, M. Clinical and pharmacologic study of preirradiation taxol administered as a 96 hour infusion in a dults with newly diagnosed glioblastoma multiforme. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 13: 179, 1994.